SCHEMBL29620865

SCHEMBL29620865

O=C(NC[C@@H](O)CO)c1ccc(Nc2ncc(-c3ccc(F)c(F)c3)o2)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCP P55072 3/20 0.40
ALOX5 P09917 1/20 0.39
GCGR P47871 7/20 0.39
MAP2K1 Q02750 5/20 0.38
DGAT1 O75907 1/20 0.38
PRKAB2 O43741 1/20 0.38
LCK P06239 1/20 0.38
SRC P12931 1/20 0.38
FLT1 P17948 1/20 0.38
KDR P35968 1/20 0.38
FLT3 P36888 1/20 0.38
PRKAG1 P54619 1/20 0.38
PRKAA2 P54646 1/20 0.38
PRKAA1 Q13131 1/20 0.38
RPS6KA1 Q15418 1/20 0.38
MKNK1 Q9BUB5 1/20 0.38
PRKAG3 Q9UGI9 1/20 0.38
PRKAG2 Q9UGJ0 1/20 0.38
PRKAB1 Q9Y478 1/20 0.38
ULK1 O75385 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28733697 1.00 VCP (0.40) VCPALOX5GCGRMAP2K1DGAT1
SCHEMBL22925647 1.00 VCP (0.40) VCPALOX5GCGRMAP2K1DGAT1
SCHEMBL22925620 0.91 ALOX5 (0.47) VCPALOX5GCGRMAP2K1DGAT1
SCHEMBL28733627 0.91 ALOX5 (0.47) VCPALOX5GCGRMAP2K1DGAT1
SCHEMBL29620962 0.91 ALOX5 (0.47) VCPALOX5GCGRMAP2K1DGAT1
SCHEMBL22925754 0.90 GCGR (0.39) VCPALOX5GCGRMAP2K1PRKAB2
SCHEMBL22925753 0.90 GCGR (0.39) VCPALOX5GCGRMAP2K1PRKAB2
SCHEMBL29620908 0.90 GCGR (0.39) VCPALOX5GCGRMAP2K1PRKAB2
SCHEMBL24637010 0.87 MAP2K1 (0.38) ALOX5GCGRMAP2K1ULK1MAP2K2
SCHEMBL22925985 0.85 TRPV1 (0.40) VCPALOX5GCGRDGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12448371-B2 Inhibitor compounds Cincera Therapeutics Pty Ltd (AU) 2025-10-21 US claimed
EP-4003986-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-06-01 EP disclosed
CN-114450281-A Inhibitor compounds 辛塞拉治疗私人有限公司 2022-05-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12448371-B2 Inhibitor compounds SERPINB1, MMP1, SSB VCP 595/4885ALOX5 1469/4885GCGR 3791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.